NEW YORK – Exagen announced after the close of the market on Monday that its first quarter revenues grew 3 percent year over year.
For the three months ended March 31, the San Diego-based autoimmune diagnostics firm posted $9.6 million in revenues, up from $9.3 million a year ago. It bested the consensus Wall Street estimate of $7.7 million.